文献速递神经肿瘤

维替泊芬靶向YAP-TEAD在胶质母细胞瘤临床前模型中显示抗侵袭疗效与生存获益

Anti-invasive efficacy and survival benefit of the YAP-TEAD inhibitor verteporfin in preclinical glioblastoma models.
PubMed 文献 · Neuro Oncol · 2022-01-01

本研究在多达8株低传代患者来源胶质母细胞瘤细胞系(含3对原发/复发配对)及原位异种移植模型中评估FDA已批准药物维替泊芬(VP)靶向YAP-TEAD的疗效。VP干扰YAP/TAZ-TEAD活性、破坏侵袭相关转录组特征并抑制迁移/侵袭,在侵袭性原位PDX模型中减少核心与浸润肿瘤负荷,长期治疗在2个PDX模型中显示无毒并带来生存获益。

要点

  • VP干扰YAP/TAZ-TEAD活性并破坏侵袭相关转录组特征。
  • VP在原发和复发GBM细胞系中抑制迁移与侵袭动态。
  • 长期VP治疗在2个PDX模型中无毒并带来生存获益。

核心结论

  • VP在临床前GBM模型中兼具抗侵袭和抗增殖疗效并带来生存获益,提示这一FDA已批准药物若重新用于GBM患者可能具有治疗价值。

研究设计与样本

  • 研究使用多达8株低传代患者来源GBM细胞系(包括3对原发/复发配对)以VP或对照处理,评估增殖、迁移、侵袭、YAP-TEAD活性及转录组学。
  • 研究使用患者来源原位异种移植(PDX)模型评估VP的脑穿透性及对肿瘤负荷和生存的影响。

主要发现

  • VP治疗干扰YAP/TAZ-TEAD活性,破坏与侵袭、上皮-间质转化及原神经-间质转化相关的转录组特征,表型模拟TEAD1敲除效应。
  • VP在原发和复发GBM细胞系中损害肿瘤迁移/侵袭动态。
  • 在侵袭性原位PDX GBM模型中,短期VP治疗持续减少核心和浸润性肿瘤负荷,并伴随肿瘤Ki67、核YAP、TEAD1及TEAD相关靶点EGFR、CDH2和ITGB1表达下降。
  • 长期VP治疗在2个PDX模型中与对照相比无毒并带来生存获益:在原发(de novo)GBM中作为单药,在复发GBM中与替莫唑胺放化疗联合,且VP治疗与MGMT甲基化增加相关。

临床怎么用

  • 基于临床前证据,VP作为FDA已批准药物,若重新用于GBM患者可能具有治疗价值,尤其值得在复发GBM中探索与替莫唑胺放化疗联合的策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Glioblastoma (GBM) remains a largely incurable disease as current therapy fails to target the invasive nature of glioma growth in disease progression and recurrence. Here, we use the FDA-approved drug and small molecule Hippo inhibitor Verteporfin (VP) to target YAP-TEAD activity, known to mediate convergent aspects of tumor invasion/metastasis, and assess the drug's efficacy and survival benefit in GBM models. METHODS: Up to 8 low-passage patient-derived GBM cell lines with distinct genomic drivers, including 3 primary/recurrent pairs, were treated with VP or vehicle (VEH) to assess in vitro effects on proliferation, migration, invasion, YAP-TEAD activity, and transcriptomics. Patient-derived orthotopic xenograft (PDX) models were used to assess VP's brain penetrance and effects on tumor burden and survival. RESULTS: VP treatment disturbed YAP/TAZ-TEAD activity; disrupted transcriptome signatures related to invasion, epithelial-to-mesenchymal, and proneural-to-mesenchymal transition, phenocopying TEAD1-knockout effects; and impaired tumor migration/invasion dynamics across primary and recurrent GBM lines. In an aggressive orthotopic PDX GBM model, short-term VP treatment consistently diminished core and infiltrative tumor burden, which was associated with decreased tumor expression of Ki67, nuclear YAP, TEAD1, and TEAD-associated targets EGFR, CDH2, and ITGB1. Finally, long-term VP treatment appeared nontoxic and conferred survival benefit compared to VEH in 2 PDX models: as monotherapy in primary (de novo) GBM and in combination with Temozolomide chemoradiation in recurrent GBM, where VP treatment associated with increased MGMT methylation. CONCLUSIONS: We demonstrate combined anti-invasive and anti-proliferative efficacy for VP with survival benefit in preclinical GBM models, indicating potential therapeutic value of this already FDA-approved drug if repurposed for GBM patients.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Barrette AM, Ronk H, Joshi T, et al. Anti-invasive efficacy and survival benefit of the YAP-TEAD inhibitor verteporfin in preclinical glioblastoma models. Neuro Oncol. 2022. PMID: 34657158. doi:10.1093/neuonc/noab244

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。